抗肿瘤血管生成可能是脑胶质瘤治疗途径之一

2013-07-19 驻地记者张献怀 中国医学论坛报

    76岁的姜女士患脑胶质瘤已无条件手术,解放军总医院第一附属医院神经外科,采用抗血管生成靶向疗法对其进行治疗,取得良好效果,肿瘤明显缩小,瘤周水肿消退,患者自觉症状消失。据该科主任张志文介绍,这是他们采用该技术治疗的第27例患者。   该患者2012年9月突然感觉左侧肢体无力

 

抗肿瘤血管生成为脑胶质瘤治疗辟新径
抗肿瘤血管生成为脑胶质瘤治疗辟新径

  76岁的姜女士患脑胶质瘤已无条件手术,解放军总医院第一附属医院神经外科,采用抗血管生成靶向疗法对其进行治疗,取得良好效果,肿瘤明显缩小,瘤周水肿消退,患者自觉症状消失。据该科主任张志文介绍,这是他们采用该技术治疗的第27例患者。

  该患者2012年9月突然感觉左侧肢体无力,走路不稳,有时跌倒,到医院检查发现,右颞部有一直径6 cm左右的占位,诊断为恶性脑胶质瘤。张志文等对患者病情及身体状况进行综合分析评估,认为根据病情应首选手术治疗,但患者有10余年的高血压和心血管病史,同时伴糖尿病,加上年龄较大,手术风险很大。患者本人也表示不愿意接受手术治疗。经多次讨论并与患者沟通,他们决定采用抗肿瘤血管生成靶向疗法为其进行治疗。经2次治疗后,磁共振复查,原肿瘤明显缩小,且基本无强化效应,瘤周水肿也明显消退,说明肿瘤已大部坏死,患者自觉头晕、肢体无力等症状消失,已于近日出院。

  张志文介绍说,该技术2009年通过美国食品与药物监管局批准并应用于恶性脑瘤治疗,取得良好效果。抗血管生成靶向疗法适用于脑恶性肿瘤,尤其对术后复发、部位特殊、或因年迈体弱身体条件差等原因而不能手术的患者,开辟了一条新的治疗途径。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2040906, encodeId=ffc0204090667, content=<a href='/topic/show?id=9c688309eeb' target=_blank style='color:#2F92EE;'>#肿瘤血管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83097, encryptionId=9c688309eeb, topicName=肿瘤血管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e4137, createdName=meichuangyi, createdTime=Tue Dec 31 05:14:00 CST 2013, time=2013-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061054, encodeId=10ce206105494, content=<a href='/topic/show?id=6ba655658cc' target=_blank style='color:#2F92EE;'>#抗肿瘤血管生成#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55658, encryptionId=6ba655658cc, topicName=抗肿瘤血管生成)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b30d401, createdName=huangshifeng, createdTime=Fri Sep 06 23:14:00 CST 2013, time=2013-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1809225, encodeId=0ce3180922512, content=<a href='/topic/show?id=57a483098c9' target=_blank style='color:#2F92EE;'>#肿瘤血管生成#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83098, encryptionId=57a483098c9, topicName=肿瘤血管生成)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0802500050, createdName=肉我只吃一口, createdTime=Sat Sep 07 11:14:00 CST 2013, time=2013-09-07, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2040906, encodeId=ffc0204090667, content=<a href='/topic/show?id=9c688309eeb' target=_blank style='color:#2F92EE;'>#肿瘤血管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83097, encryptionId=9c688309eeb, topicName=肿瘤血管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e4137, createdName=meichuangyi, createdTime=Tue Dec 31 05:14:00 CST 2013, time=2013-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061054, encodeId=10ce206105494, content=<a href='/topic/show?id=6ba655658cc' target=_blank style='color:#2F92EE;'>#抗肿瘤血管生成#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55658, encryptionId=6ba655658cc, topicName=抗肿瘤血管生成)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b30d401, createdName=huangshifeng, createdTime=Fri Sep 06 23:14:00 CST 2013, time=2013-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1809225, encodeId=0ce3180922512, content=<a href='/topic/show?id=57a483098c9' target=_blank style='color:#2F92EE;'>#肿瘤血管生成#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83098, encryptionId=57a483098c9, topicName=肿瘤血管生成)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0802500050, createdName=肉我只吃一口, createdTime=Sat Sep 07 11:14:00 CST 2013, time=2013-09-07, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2040906, encodeId=ffc0204090667, content=<a href='/topic/show?id=9c688309eeb' target=_blank style='color:#2F92EE;'>#肿瘤血管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83097, encryptionId=9c688309eeb, topicName=肿瘤血管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e4137, createdName=meichuangyi, createdTime=Tue Dec 31 05:14:00 CST 2013, time=2013-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061054, encodeId=10ce206105494, content=<a href='/topic/show?id=6ba655658cc' target=_blank style='color:#2F92EE;'>#抗肿瘤血管生成#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55658, encryptionId=6ba655658cc, topicName=抗肿瘤血管生成)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b30d401, createdName=huangshifeng, createdTime=Fri Sep 06 23:14:00 CST 2013, time=2013-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1809225, encodeId=0ce3180922512, content=<a href='/topic/show?id=57a483098c9' target=_blank style='color:#2F92EE;'>#肿瘤血管生成#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83098, encryptionId=57a483098c9, topicName=肿瘤血管生成)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0802500050, createdName=肉我只吃一口, createdTime=Sat Sep 07 11:14:00 CST 2013, time=2013-09-07, status=1, ipAttribution=)]

相关资讯

Oncologist:贝伐单抗联合化疗可能提高疗效

针对肿瘤新生血管形成或血管生成的治疗手段在癌症治疗中占有重要地位,贝伐单抗等针对血管内皮生长因子(VEGF)的单克隆抗体生物制剂在临床上已被广泛运用。 抗血管生成疗法的基本原理是如果肿瘤获得新的血液供应能力有限,那么它们的生长和转移能力也会受到限制。更多的证据表明,修饰和/或“正常化”不规则的肿瘤血管,减少缺氧可加强肿瘤细胞毒性化疗(CT)的功效。 事实上,对于转移性大肠直肠癌,贝伐单抗联合C